Sun Pharmaceutical Industries’ one of the wholly owned subsidiaries has agreed to acquire shares of Tarsius Pharma (Tarsius), Israel, by way of subscription of 345,622 ordinary shares of nominal value of NIS 0.01 each, representing 18.75% of shares of Tarsius, on a fully diluted basis.
Tarsius is an Israel based early stage Research and Development (R&D) company focusing on development of drug candidates in the field of Ophthalmology. The cost of acquisition is $3 million and indicative time period for completion of the acquisition is before September 15, 2018.
Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.50 |
| Dr. Reddys Lab | 1221.45 |
| Cipla | 1230.00 |
| Zydus Lifesciences | 930.90 |
| Lupin | 2323.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: